Genetic and Clinical Determinants of MACE and Haemorrhage in Antiplatelet Therapy: Insights from Pharmacogenomic Analysis

Author:

ZHAO Jun1,Wang Yubo1ORCID,YUAN Shuangli,Li Muyun,Feng Wenling,Li Jing,Berdi Aliye,Kou Yulian,Chen Wenwen,Yuan Yuan

Affiliation:

1. The First Affiliated Hospital of Xinjiang Medical University; Xinjiang Key Laboratory of Clinical Drug Research

Abstract

Abstract

Background: Variability in responses to clopidogrel and aspirin therapy for coronary artery disease has driven interest in pharmacogenomics. This study investigates the role of genetic variants in CYP2C19, ABCB1, and PON1 in predicting adverse cardiovascular events and guiding personalised antiplatelet therapy. Methods: A retrospective cohort study designed to compare the effectiveness and safety of the risk levels from CYP2C19 (*2, *3, *17), ABCB1 C3435T, and PON1 Q192R polymorphisms. The primary outcome was the incidence of haemorrhage and major adverse cardiovascular events (MACE). Kaplan Merir curves and Cox regression with IPTW adjustments were used for analysis. Results: Group A (treatment consistent with multigene testing) showed significantly lower MACE incidence than Group B. Multigene testing more accurately predicted clopidogrel effectiveness than single-gene testing and reduced adverse events without increasing haemorrhagic risk. Conclusion: Multigene-guided antiplatelet therapy is more effective in reducing adverse cardiovascular events. Further prospective studies are needed to validate these findings, incorporating genetic, environmental, and lifestyle factors for a comprehensive personalised medicine approach.

Publisher

Springer Science and Business Media LLC

Reference27 articles.

1. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Lawton JS;Circulation,2022

2. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel Pharmacogenetics. Circulation Cardiovascular interventions. 2019;12(4):e007811.

3. Genetic and non-genetic factors affecting the response to clopidogrel therapy;Karaźniewicz-Łada M;Expert opinion on pharmacotherapy,2012

4. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy;Shuldiner AR;Jama,2009

5. Research Progress on Clinical Gene Polymorphism of Clopidogrel Resistance;Yue-mei SUN;Chinese Pharmaceutical Journal,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3